News
The day at a glance · 3 min read
Mood · Risk-On
+72
Sentiment, −100 to +100
UnitedHealth Q3 Revenue
$112.7b
UnitedHealth Q3 Net Income
$4.1b
UnitedHealth FY EPS Guidance
$19.50
Key driverStrong quarterly earnings from major healthcare names and positive late-stage trial data across oncology and rare disease franchises
Daily briefHealthcare· Money365.Market AI ·

Healthcare Earnings Drive Sector Rally

UnitedHealth, Regeneron, and J&J beat expectations; AbbVie reports cancer trial progress; Pfizer expands Tukysa approval

Big Pharma & Biotech Earnings

Bullish

Regeneron Q2 Revenue

$4.29b+16.7%

J&J Q3 Sales

$25,399m

J&J Q3 Net Income

$210m
01UNH▲ +2.79%
UnitedHealth Group (UNH) reported third quarter 2026 revenue of $112.7b with net income of $4.1b and raised full year 2026 earnings guidance to at least $19.50 in diluted EPS and more than $17.65b in net earnings attributable to common shareholders. The managed care giant continued its long running buyback program, retiring about 3.5m shares in the latest quarter and bringing cumulative repurchases to roughly 737m shares since 2006.
02REGN
Regeneron Pharmaceuticals (REGN) reported Q2 revenue of $4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The 84 week OPTIMA readout suggests a sustained effect in limiting new rogue bone formation and flare ups while maintaining a generally consistent safety profile. Regeneron flagged ongoing regulatory filings in additional markets and a planned pediatric trial to extend Pasatru access to younger FOP patients. The shares have rallied about 12.4% since the release, with a 7-day share price return of 7.68% and a 90-day return of 17.68%.
03JNJ
Johnson & Johnson (JNJ) reported third quarter 2026 sales of $25,399 million and net income of $210 million, raised its full year outlook, and affirmed a $1.34 per share fourth quarter dividend payable in December 2026. Strong demand for TREMFYA, early momentum for ICOTYDE, and continued focus on oncology helped offset weaker MedTech performance and international pricing pressure.

Oncology Pipeline Advances

Bullish

AbbVie DLBCL Risk Reduction

51%

AbbVie 5-Year Return

211.2%
01ABBV
AbbVie (ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCORE DLBCL-2 study showed a statistically significant reduction in the risk of disease progression or death versus R-CHOP alone, with trial data pointing to a 51% risk reduction in high risk diffuse large B cell lymphoma patients. AbbVie has returned 211.2% over the past 5 years.
02PFE
Pfizer (PFE) recently secured expanded FDA approval for TUKYSA as a chemotherapy free maintenance option in HER2 positive metastatic breast cancer and reported a wide slate of infectious disease vaccine data, including late stage Lyme, pneumococcal and RSV studies. The breadth of vaccine and oncology updates points to Pfizer leaning heavily on late stage pipelines and real world evidence to support future portfolio mix as older products face patent expiry and COVID sales pressure.
03BMY
Bristol Myers Squibb (BMY) is executing a visible portfolio transition, with its Growth Portfolio now surpassing Legacy Portfolio.

MedTech & Diagnostics Market Outlook

Bullish

Immuno-Oncology Diagnostics Market 2030

$11.1B
01TMO▲ +3.46%
A new market intelligence report forecasts the immuno-oncology diagnostics market to reach $11.1B by 2030 as checkpoint inhibitor and cell therapy pipelines drive demand for companion tests. The report tracks Roche Diagnostics, Thermo Fisher (TMO), Illumina, Agilent and Guardant Health among 132 companies, with forecasts by assay type, technology, customer and country.
02TMO▲ +3.46%
A separate 307-page intelligence report maps surging demand for targeted omics technologies in the global proteomic biomarker analytics market, profiling strategic moves by Danaher, Roche, and Thermo Fisher Scientific (TMO) across global clinical landscapes. The report notes that where genomics cannot find all the answers proteomics is stepping up to the plate, with double-digit growth boosting cancer diagnostics and drug discovery.

Equity Performance & Analyst Commentary

Bullish

Moderna Price Target (Goldman)

$137+from $120

Gilead Close

$157.48+2.57%

Intuitive Surgical Close

$427.86+1.81%

Amgen Close

$434.03+1.86%
01MRNA▲ +4.51%
Moderna (MRNA) stock hit fresh 52-week highs as Goldman Sachs analyst Salveen Richter raised the firm's price target on Moderna to $137 from $120 while maintaining a Neutral rating.
02GILD
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving higher than the broader market. The stock is trading near its 52-week high, indicating some degree of investor confidence, business improvements, or favorable market conditions.
03ISRG
Intuitive Surgical (ISRG) reached $427.86 at the closing of the latest trading day, reflecting a gain compared to its last close.
04AMGN
Amgen (AMGN) settled at $434.03, representing a change from its previous close and exceeding market returns.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy